Home > Muzaffar Qazilbash, EHA 2018 – Busulfan + melphalan in high-risk multiple myeloma
Multiple Myeloma

Muzaffar Qazilbash, EHA 2018 – Busulfan + melphalan in high-risk multiple myeloma

Published Online: June 20th 2018

Muzaffar Qazilbash from The University of Texas MD Anderson Cancer Center talks to touchONCOLOGY about investigating busulfan plus melphalan as a potential combination therapy for high-risk multiple myeloma.

1. What was the rationale for using a combined busulfan and melphalan conditioning regimen compared with melphalan alone for multiple myeloma? (0:08)

2. Could you tell us a little about the study design and what doses were used? (0:46)

3. What were the efficacy findings of the study? (1:57)

4. What was the safety profile of this combination? (3:02)

5. What were the limitations of this study and what further study is needed? (4:13)

Speaker disclosures: Muzaffar Qazilbash has nothing to disclose in relation to this video interview.

Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018

Share this Video
Related Videos In Multiple Myeloma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar